stockportfolio.pro
Capricor Therapeutics, Inc. (CAPR)
Healthcare · Biotechnology · NasdaqGS
Capricor Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.00M | $2.67M | $1.67M | $1.01M | $310,250 | $244,898 | $2.55M | $25.18M | $22.27M | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-18.81M | $2.43M | $-15.19M | $-7.64M | $-13.66M | $-20.02M | $-29.02M | $-22.29M | $-40.47M | $-105.04M |
| Net margin | -470.3% | 91.2% | -908.9% | -760.4% | -4401.9% | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
Source: Capricor Therapeutics, Inc. SEC filings (10-K). 20 years of history available in the interactive view.
Explore 20 years of Capricor Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CAPR in your portfolio →
Capricor Therapeutics, Inc. financial history by metric
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Capricor Therapeutics, Inc. — frequently asked questions
What is Capricor Therapeutics, Inc.'s revenue?
Capricor Therapeutics, Inc. (CAPR) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Capricor Therapeutics, Inc. profitable?
No — CAPR reported a net loss of $-105.04M in fiscal 2025.
What is CAPR's P/E ratio?
Capricor Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Capricor Therapeutics, Inc. have?
As of fiscal year 2025, CAPR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Capricor Therapeutics, Inc.'s market cap?
Capricor Therapeutics, Inc. (CAPR) has a market capitalization of about $1.44B, based on the latest data in our nightly-refreshed cache.
When does Capricor Therapeutics, Inc.'s fiscal year end?
CAPR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Capricor Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 20 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.